Tae-Wan Kim

Tae-Wan Kim, PhDColumbia University
...
DR. KIM has been working with genetic mutations that are associated with early-onset familial Alzheimer's disease (FAD).These mutations increase production of ,-amyloid (A,) by increasing cleavage of amyloid precursor protein (APP) by ,- or ,-secretase.Specifically, Dr. Kim has been studying the "Swedish'" FAD mutation in APP, which results in increased ,-secretase cleavage of APP, and mutations in presenilins, which affect the ,-secretase pathway, leading to increased production of highly amyloidogenic A,42.Applying the relatively new technique of RNA interference (RNAi), he has developed small interfering RNAs (siRNA) that can selectively suppress the FAD allele without affecting the wild-type allele.His group has also developed a lentivirus-based delivery system.

Drs. Paul Greengard of The Rockefeller University, David Holtzman of Washington University at St. Louis and Dr. Tae-Wan Kim of Columbia University Medical Center are investigating the relationship between oligomers and neuronal synapse function.

2. Tae Wan Kim Columbia University, USA

Tae-Wan Kim, Ph.D. Alzheimer's Disease ResearchColumbia University

Dr. Tae-Wan Kim of Columbia University Medical Center, both in New York City.

Two more researchers, Sam Gandy of Mount Sinai Medical School and Tae-Wan Kim of Columbia University, joined the Oligomer Collaborative and were also funded in August.
...
Dr. Tae-Wan KimColumbia University Medical Center

Tae-Wan Kim, Ph.D. Columbia University

Tae-Wan Kim, PhD

Tae-Wan Kim, PhDColumbia University

Tae-Wan Kim, Ph.D.Columbia University